View Financial HealthBide Pharmatech 配当と自社株買い配当金 基準チェック /36Bide Pharmatech配当を支払う会社であり、現在の利回りは2.09%で、収益によって十分にカバーされています。主要情報2.1%配当利回り2.1%バイバック利回り総株主利回り4.2%将来の配当利回り2.1%配当成長-1.6%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向59%最近の配当と自社株買いの更新お知らせ • Feb 10Bide Pharmatech Co., Ltd. (SHSE:688073) announces an Equity Buyback for CNY 100 million worth of its shares.Bide Pharmatech Co., Ltd. (SHSE:688073) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 72.30 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and special loans. The program will be valid for 6 months.すべての更新を表示Recent updatesBoard Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 23Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026, at 09:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai Chinaお知らせ • Mar 30Bide Pharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Bide Pharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026お知らせ • Dec 26Bide Pharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Sep 30Bide Pharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025Bide Pharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025お知らせ • Jun 30Bide Pharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Bide Pharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025お知らせ • Apr 24Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai Chinaお知らせ • Mar 28Bide Pharmatech Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025Bide Pharmatech Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025お知らせ • Feb 10Bide Pharmatech Co., Ltd. (SHSE:688073) announces an Equity Buyback for CNY 100 million worth of its shares.Bide Pharmatech Co., Ltd. (SHSE:688073) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 72.30 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and special loans. The program will be valid for 6 months.お知らせ • Jan 22Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd.Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd. on January 21, 2025. The consideration consists of common equity of Bide Pharmatech Co., Ltd. to be issued for common equity of Zhuhai Weibo Investment Co., Ltd. As part of consideration, an undisclosed value is paid towards common equity of Zhuhai Weibo Investment Co., Ltd.お知らせ • Dec 27Bide Pharmatech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥42.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in China.Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.33 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.36 (up from CN¥0.33 in 3Q 2023). Revenue: CN¥279.2m (down 1.1% from 3Q 2023). Net income: CN¥32.0m (up 8.2% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥33.82, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥44.40 per share.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥37.43, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.54 per share.お知らせ • Sep 30Bide Pharmatech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Bide Pharmatech Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024Reported Earnings • Aug 29Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.51 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.51 in 2Q 2023). Revenue: CN¥269.5m (flat on 2Q 2023). Net income: CN¥25.8m (down 45% from 2Q 2023). Profit margin: 9.6% (down from 17% in 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.お知らせ • Jun 29Bide Pharmatech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024Bide Pharmatech Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024お知らせ • May 15Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai ChinaReported Earnings • Apr 27First quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.41 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.41 in 1Q 2023). Revenue: CN¥262.7m (up 4.0% from 1Q 2023). Net income: CN¥26.1m (down 29% from 1Q 2023). Profit margin: 9.9% (down from 15% in 1Q 2023). Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.お知らせ • Mar 29Bide Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024Bide Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024Valuation Update With 7 Day Price Move • Mar 27Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥36.16, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Pharmaceuticals industry in China.Reported Earnings • Feb 03Full year 2023 earnings released: EPS: CN¥1.24 (vs CN¥1.98 in FY 2022)Full year 2023 results: EPS: CN¥1.24 (down from CN¥1.98 in FY 2022). Revenue: CN¥1.09b (up 31% from FY 2022). Net income: CN¥113.0m (down 23% from FY 2022). Profit margin: 10% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.Valuation Update With 7 Day Price Move • Feb 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥39.88, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 16x in the Pharmaceuticals industry in China.お知らせ • Dec 30Bide Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Meng Zhang was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 688073が配当金を支払っている期間は 10 年未満です。増加する配当: 688073の配当金は増加していますが、同社は3年間しか配当金を支払っていません。配当利回り対市場Bide Pharmatech 配当利回り対市場688073 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (688073)2.1%市場下位25% (CN)0.4%市場トップ25% (CN)1.9%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (688073) (最長3年)2.1%注目すべき配当: 688073の配当金 ( 2.09% ) はCN市場の配当金支払者の下位 25% ( 0.36% ) よりも高くなっています。高配当: 688073の配当金 ( 2.09% ) はCN市場 ( 1.94% ) の配当支払者の中で上位 25% に入っています。株主への利益配当収益カバレッジ: 688073の配当金は、合理的な 配当性向 ( 59.3% ) により、利益によって賄われています。株主配当金キャッシュフローカバレッジ: 688073は高い 現金配当性向 ( 281.3% ) のため、配当金の支払いはキャッシュフローで十分にカバーされていません。高配当企業の発掘7D1Y7D1Y7D1YCN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 13:04終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bide Pharmatech Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Yuan Yuan SunIndustrial Securities Co. Ltd.Hanyang HuangIndustrial Securities Co. Ltd.
お知らせ • Feb 10Bide Pharmatech Co., Ltd. (SHSE:688073) announces an Equity Buyback for CNY 100 million worth of its shares.Bide Pharmatech Co., Ltd. (SHSE:688073) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 72.30 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and special loans. The program will be valid for 6 months.
Board Change • May 20High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. R&D Director and Supervisor Ronghao Li is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 23Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026Bide Pharmatech Co., Ltd., Annual General Meeting, May 13, 2026, at 09:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China
お知らせ • Mar 30Bide Pharmatech Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026Bide Pharmatech Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026
お知らせ • Dec 26Bide Pharmatech Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Sep 30Bide Pharmatech Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025Bide Pharmatech Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025
お知らせ • Jun 30Bide Pharmatech Co., Ltd. to Report First Half, 2025 Results on Aug 22, 2025Bide Pharmatech Co., Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
お知らせ • Apr 24Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025Bide Pharmatech Co., Ltd., Annual General Meeting, May 14, 2025, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China
お知らせ • Mar 28Bide Pharmatech Co., Ltd. to Report Q1, 2025 Results on Apr 24, 2025Bide Pharmatech Co., Ltd. announced that they will report Q1, 2025 results on Apr 24, 2025
お知らせ • Feb 10Bide Pharmatech Co., Ltd. (SHSE:688073) announces an Equity Buyback for CNY 100 million worth of its shares.Bide Pharmatech Co., Ltd. (SHSE:688073) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 72.30 per share. The purpose of the program is to improve the company's long-term incentive mechanism, fully mobilize the enthusiasm of the employees, and jointly promote the company's long-term development. The repurchased shares will be used for employee stock ownership plans or equity incentive plans, otherwise will be cancelled if the company fails to transfer them within the time limit stipulated by relevant laws and regulations. The program will be funded from company's own funds and special loans. The program will be valid for 6 months.
お知らせ • Jan 22Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd.Bide Pharmatech Co., Ltd. (SHSE:688073) agreed to acquire an unknown minority stake in Zhuhai Weibo Investment Co., Ltd. from Vivo (Suzhou) Health Industry Investment Fund (Limited Partnership) managed by Vivo Capital, LLC and Vivo Equity Investment Management (Shanghai) Co. Ltd. on January 21, 2025. The consideration consists of common equity of Bide Pharmatech Co., Ltd. to be issued for common equity of Zhuhai Weibo Investment Co., Ltd. As part of consideration, an undisclosed value is paid towards common equity of Zhuhai Weibo Investment Co., Ltd.
お知らせ • Dec 27Bide Pharmatech Co., Ltd. to Report Fiscal Year 2024 Results on Apr 24, 2025Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2024 results on Apr 24, 2025
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improves as stock rises 17%After last week's 17% share price gain to CN¥42.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 18x in the Pharmaceuticals industry in China.
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: CN¥0.36 (vs CN¥0.33 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.36 (up from CN¥0.33 in 3Q 2023). Revenue: CN¥279.2m (down 1.1% from 3Q 2023). Net income: CN¥32.0m (up 8.2% from 3Q 2023). Profit margin: 12% (up from 11% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥33.82, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥44.40 per share.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥37.43, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.54 per share.
お知らせ • Sep 30Bide Pharmatech Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024Bide Pharmatech Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024
Reported Earnings • Aug 29Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.51 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.51 in 2Q 2023). Revenue: CN¥269.5m (flat on 2Q 2023). Net income: CN¥25.8m (down 45% from 2Q 2023). Profit margin: 9.6% (down from 17% in 2Q 2023). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.
お知らせ • Jun 29Bide Pharmatech Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024Bide Pharmatech Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024
お知らせ • May 15Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024Bide Pharmatech Co., Ltd., Annual General Meeting, Jun 03, 2024, at 14:30 China Standard Time. Location: 6F, Building 3, No. 999, Xiangyin Road, Yangpu District, Shanghai China
Reported Earnings • Apr 27First quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.41 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.29 (down from CN¥0.41 in 1Q 2023). Revenue: CN¥262.7m (up 4.0% from 1Q 2023). Net income: CN¥26.1m (down 29% from 1Q 2023). Profit margin: 9.9% (down from 15% in 1Q 2023). Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.
お知らせ • Mar 29Bide Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024Bide Pharmatech Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥36.16, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Pharmaceuticals industry in China.
Reported Earnings • Feb 03Full year 2023 earnings released: EPS: CN¥1.24 (vs CN¥1.98 in FY 2022)Full year 2023 results: EPS: CN¥1.24 (down from CN¥1.98 in FY 2022). Revenue: CN¥1.09b (up 31% from FY 2022). Net income: CN¥113.0m (down 23% from FY 2022). Profit margin: 10% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.
Valuation Update With 7 Day Price Move • Feb 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to CN¥39.88, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 16x in the Pharmaceuticals industry in China.
お知らせ • Dec 30Bide Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024Bide Pharmatech Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024
Board Change • Nov 17Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Meng Zhang was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.